Literature DB >> 808600

Animal pharmacology of Wy-16,225, a new analgesic agent.

J L Malis, M E Rosenthale, M I Gluckman.   

Abstract

The analgesic potency of Wy-16,225 in rodents and primates is greater than morphine while antagonist potency is slightly less than that of nalorphine. The compound demonstrates properties unlike those of standard narcotic and narcotic antagonist agents and has a wide margin of safety. In dependence liability studies, Wy-16,225 neither acutely substitutes for morphine nor produces direct dependence when administered chronically to monkeys. Wy-16,225 has no anti-inflammatory properties, is not constipating in rats, has no significant cardiovascular toxicity in dogs and produces minimal respiratory depression in monkeys.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 808600

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Agonist-antagonist opioids: theory and clinical practice.

Authors:  C Rosow
Journal:  Can J Anaesth       Date:  1989-05       Impact factor: 5.063

Review 2.  Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J J O'Brien; P Benfield
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 3.  Dezocine as a potent analgesic: overview of its pharmacological characterization.

Authors:  Rong-Rong Ye; Shuang Jiang; Xu Xu; Yan Lu; Yu-Jun Wang; Jing-Gen Liu
Journal:  Acta Pharmacol Sin       Date:  2021-11-04       Impact factor: 7.169

4.  Double-blind placebo-controlled comparison of dezocine and morphine for post-operative pain relief.

Authors:  S K Pandit; S P Kothary; U A Pandit; N R Kunz
Journal:  Can Anaesth Soc J       Date:  1985-11

5.  Dezocine promotes T lymphocyte activation and inhibits tumor metastasis after surgery in a mouse model.

Authors:  Qiang Song; Geng Liu; Dongyi Liu; Chang Feng
Journal:  Invest New Drugs       Date:  2020-03-13       Impact factor: 3.850

6.  Novel molecular targets of dezocine and their clinical implications.

Authors:  Renyu Liu; Xi-Ping Huang; Alexei Yeliseev; Jin Xi; Bryan L Roth
Journal:  Anesthesiology       Date:  2014-03       Impact factor: 7.892

7.  Nalorphine's effect under several schedules of electric shock titration.

Authors:  L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

8.  Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.

Authors:  Yong-Xiang Wang; Xiao-Fang Mao; Teng-Fei Li; Nian Gong; Ma-Zhong Zhang
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

9.  Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: A randomized, controlled, double-blind trial.

Authors:  Peng Zhao; Zhuoxi Wu; Chunrui Li; Guiying Yang; Jinping Ding; Kai Wang; Mingming Wang; Lijuan Feng; Guangyou Duan; Hong Li
Journal:  PLoS One       Date:  2020-05-26       Impact factor: 3.240

10.  "I'll Be Back": The Resurrection of Dezocine.

Authors:  Wayne E Childers; Magid A Abou-Gharbia
Journal:  ACS Med Chem Lett       Date:  2021-05-19       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.